Cargando…
Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity
Carbidopa is a drug that blocks conversion of levodopa to dopamine outside of central nervous system (CNS) and thus inhibits unwanted side effects of levodopa on organs located outside of CNS during management of Parkinson’s Disease (PD). PD is associated with increased expression of inflammatory ge...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595290/ https://www.ncbi.nlm.nih.gov/pubmed/28898256 http://dx.doi.org/10.1371/journal.pone.0183484 |